Zetia Articles
Schering-Plough sees 2nd-qtr losses
26 July 2004
OTC statins "only way for budget-curbed GPs"
26 July 2004
NZ to fund Merck & Co/ S-P cholesterol drugs
21 June 2004
Dual Ezetrol/Zocor therapy effective
3 May 2004
Merck & Co/S-P's Inegy OKed in Germany
12 April 2004
Merck & Co 4th-qtr in line with estimates; net income down 23%
2 February 2004
Intron slump, charges lead to S-P loss
2 February 2004
Stock Commentary - New York
22 December 2003
Generics push S-P profits down 71%
28 July 2003
Stock Commentary - New York
17 March 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
More Zetia trials support efficacy
20 May 2002
New Zetia data back up product rationale
13 May 2002
Zetia boosts response to statin therapy
25 March 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Stock Commentary - New York
14 January 2002
Merck, S-P file in USA for cholesterol drug
7 January 2002
Merck & Co and S-P expand cholesterol partnership
7 January 2002
Merck & Co and S-P expand cholesterol partnership
20 December 2001
Merck points to robust pipeline despite near-term profits warning
12 December 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
